STAT
statnews.com · EN
- 52posts a week
- 9 Novlast post
- #1in Health
Reporting from the frontiers of health and medicine
Subscribe
Latest posts
Opinion: STAT+: CVS’ split doesn’t fix its fundamental problem
CVS’ split into two doesn’t fix its fundamental problem, writes Judi Health CEO A.J. Loiacono.
Liver experts finally agree on what acute-on-chronic liver failure is
"Patients are suffering with this condition that everyone has their own way of defining."
STAT+: Democrats begin asking: How far can we go on health care?
Many in the party are pushing for Democratic lawmakers to go big on health care, but their dreams may crash into reality.
AI chatbots aren’t therapists. But can they finally get men to open up?
AI chatbots are imperfect therapists. But can they finally get men to talk?
Survival after sudden cardiac arrest didn’t improve despite training bystanders, emergency responders
A new study found survival after sudden cardiac arrest didn’t improve with advance training of responders — but researchers aren't ready to shut the door on the possibility.
STAT+: Why the latest heart drug failures should make us all more skeptical of AI hype
Once again, a hot new technology that was supposed to speed up drug research has fallen flat.
Lowering blood pressure after stroke or with diabetes poses challenges, in research and practice
High blood pressure is known as the silent killer. Researchers are finding new ways to fight back.
STAT+: BIO joins the legal fight against Medicare pilot that ties drug prices to peer countries
The model is a test of Trump's most-favored nation approach to drug pricing, though its impact is likely to be limited.
STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy
Medical mystery at the AHA conference: A Novartis drug lowered a risk marker for cardiovascular disease but did not lower chance of heart attack or stroke.
STAT+: Despite Novo drug’s failure, cardiologists say they will still pursue anti-inflammatories
“These results, the fact that they're negative, does not invalidate that inflammation plays a very important role in cardiovascular disease."
STAT+: States sue Trump administration again to delay Medicaid work requirements
The Trump administration is facing another lawsuit over its sweeping changes to Medicaid less than a week after a federal judge ruled that implementation of work requirements would cause “irreparable…
STAT+: MAHA leader Calley Means castigates White House officials as bending to industry
Calley Means, a MAHA leader who just resigned from the Trump administration, says Americans "are being duped and gaslighted and lied to."
Two incoming lawmakers plan to defend health equity from Trump administration cuts
Two newly elected lawmakers with science backgrounds hope to push back against Trump administration cuts to health equity programs.
STAT+: Democrats’ midterm landslide spells relief for hospitals
Democrats are likely to focus on reversing Medicaid cuts and expanding insurance coverage, giving a boost to health care providers.
Democrats’ midterm victory, and a questionable fertility procedure
How will the midterm results affect drug pricing policy? And why are women traveling to fertility clinics abroad? Find out on the new episode of "The Readout LOUD" podcast.
STAT+: Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
STAT+: Zolgensma tumor cases show risks of a common gene therapy tool
New cases show AAV gene therapies like Zolgensma carry tumor risks, raising key concerns for SMA patients and gene therapy researchers in general.
STAT+: Amgen’s Repatha linked to fewer heart attacks
Pithy intro text about the biopharma milieu. Novartis cites more tumor reports after Zolgensma Novartis has disclosed seven previously unreported cases of tumors in children who received Zolgensma, its gene therapy…
New evidence for ancient cannabis use
A new paper, published yesterday in Science, offers compelling evidence of ritual cannabis use in a 2,800-year-old Siberian tomb.
STAT+: Pharmalittle: We’re reading about a Novartis gene therapy, faster U.K. drug reviews, and more
Novartis acknowledged seven instances of tumors being found in children who were treated with Zolgensma for spinal muscular atrophy
In the directory since 25 Sept 2026 · last checked 9 Nov 2026 · RSS